Tixagevimab and cilgavimab: Can we see more recommendations for monoclonal antibodies beyond COVID-19 vaccination

Abstract

Nearly three years after its detection, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome CoV-2, is still a life-threatening global pandemic health disease that contributed to a high progression and mortality. This imposes the scientific researching efforts to hold intense interest directed to explore for the development and optimizing different interventions to COVID-19 infection. This commentary summarizes the potential clinical benefits for the recently authorized immunotherapy combination of tixagevimab and cilgavimab monoclonoal antibodies for the prevention and treatment of COVID-19.